Mesial temporal sclerosis: pathogenesis and significance

Z Liu1, M Mikati, G L Holmes

  • 1Department of Neurology, Harvard Medical School, Children's Hospital, Boston, Massachusetts 02115, USA.

Pediatric Neurology
|January 1, 1995
PubMed

Insights

Mesial temporal sclerosis (MTS) is linked to temporal lobe epilepsy, developing over time after prolonged or complex febrile seizures. This condition arises from excessive neuronal excitability and glutamate release, particularly in adults.

Area of Science:

  • Neurology
  • Epileptology
  • Pathology

Background:

  • Mesial temporal sclerosis (MTS) is a common finding in temporal lobe epilepsy (TLE).
  • MTS is rarely seen in children under ten but becomes more prevalent in adolescence.
  • The etiology of MTS is debated, but evidence suggests it is both a cause and consequence of seizures.

Purpose of the Study:

  • To explore the relationship between seizures and the development of MTS.
  • To investigate the underlying mechanisms of MTS formation.
  • To understand age-related differences in MTS development.

Main Methods:

  • Review of clinical studies on epilepsy patients.
  • Experimental administration of epileptogenic agents to adult and immature animals.
  • Analysis of the role of excitatory amino acids, specifically glutamate, in neuronal damage.

Main Results:

  • Prolonged seizures or complicated febrile seizures are implicated in MTS development.
  • Excessive glutamate release leads to excitotoxicity, neuronal depolarization, and calcium influx.
  • Agents causing MTS in adult animals do not induce it in immature animals, suggesting developmental differences.

Conclusions:

  • MTS is a consequence of seizures, requiring time for full lesion development.
  • While seizures pose a risk, the development of MTS is age-dependent.
  • Glutamate-mediated excitotoxicity is a key mechanism in MTS pathogenesis, with variations observed between adult and immature subjects.

Related Concept Videos

Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Secondary Spinal Cord Injury llI: Pathophysiology01:25

Secondary Spinal Cord Injury llI: Pathophysiology

Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...